Alnylam Pharmace. buy Subdi
Start price
10.09.18
/
50%
€98.87
Target price
12.09.18
€132.40
Performance (%)
-9.59%
End price
12.09.18
€89.39
Summary
This prediction ended on 12.09.18 with a price of €89.39. With a performance of -9.59%, the BUY prediction by Subdi finished with a loss. Subdi has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 4.797% | 4.797% | -3.119% | 45.158% |
| iShares Core DAX® | -2,49 % | 0,32 % | 0,75 % | 51,02 % |
| iShares Nasdaq 100 | -4,40 % | 1,59 % | 32,09 % | 87,97 % |
| iShares Nikkei 225® | -4,29 % | 0,97 % | 50,00 % | 61,27 % |
| iShares S&P 500 | -2,20 % | 2,00 % | 22,60 % | 65,12 % |
Comments by Subdi for this prediction
In the thread Alnylam Pharmace. diskutieren
Subdi stimmt der Buy-Einschätzung von Subdi zu
Subdi stimmt am 10.09.2018 der Buy-Einschätzung von Subdi mit dem Kursziel 146,78$ zu.
Überschrift: Subdi stimmt der Buy-Einschätzung von stratec zu
(Vom Mitglied beendet)
Stopped prediction by Subdi for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€70.57
27.10.18
27.10.18
€132.40
08.11.18
08.11.18
-6.88%
08.11.18
08.11.18
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€110.65
31.08.18
31.08.18
€132.40
06.09.18
06.09.18
-4.71%
06.09.18
06.09.18